- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Indian Pharma Market sees 12.1 percent growth in August: AIOCD-AWACS Report
New Delhi: The Indian Pharmaceutical Market (IPM) saw significant growth of 12.1 percent in value and 4.8 percent in volume, in the month of August, 2022, says market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS).
"A robust 12% growth of the IPM seems to be supported by a good volume driven growth for majority of the therapy areas," the AWACS report said. It also claimed that COVID influence had reduced drastically by July 21 last year and most of the therapies had started following the normal seasonal trends. For the month of August 22, price increase led growth seems to be slightly higher than the volume growth.
IPM recorded sales of Rs 16,239 crore for August month, and most of the therapies showed a well balanced double digit value and unit growth.
The fastest growing categories were cardiac which grew at 13 percent, anti-infectives - 13 percent and gastrointestinal - 12 percent. Anti-diabetes and vitamins grew 9 percent respectively. The month of August saw very few launches in the the Sitagliptin Generics segment.
Mankind, Cipla and Glenmark stood out with double digit value and unit growth among top 20 corporate. Meanwhile, Augmentin by GSK, USV's Glycomet GP and Mixtard of Abbott maintained the top ranks at month and MAT level. These remained top 3 selling brands in India.
Further, as per the market research firm, the pharma industry has increased the prices by 10% on drugs under price control, along with monsoon linked infectious diseases due to Wholesale Pricing Index (WPI) inflation-linked price hike permitted by the government.
Key Takeaways
• The initial surge of new introductions and quantity pick up in the Sitagliptin market seems to have plateaued in the month of August. This may be because of the limited patient population available.
• There is a gradual shift seen from Sulphonylureas to DPP4-i over a period of time
• Majority of the therapies in the IPM show a robust value and unit growth indicating strong positive trendlines in the coming months
Medical Dialogues team had earlier reported that IPM had witnessed a significant growth of 14.1% in value and 7.3% in volume in the month of July across all the therapy areas.
Also Read: Indian Pharma Market Sees 14.1 Percent Growth In July Sales: AIOCD-AWACS Report
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751